Browsing Tag
Food and Drug Administration
31 posts
FDA shocks Neurotech with rejection of orphan drug status for life-changing PANDAS/PANS treatment
Neurotech International Limited is facing an uphill battle after the United States Food and Drug Administration (FDA) declined…
LifeVantage stock soars on game-changing GLP-1 study results – here’s what you need to know
Shares of LifeVantage Corporation have jumped 8.2% after the company announced encouraging results from a study on its…
This new FDA-approved insulin pump just sent Modular Medical’s stock soaring 27%—Find out why!
Shares of Modular Medical, Inc. soared by 27% to reach $2.49, surpassing its previous 52-week high of $2.22,…
FDA approves Janssen’s TECVAYLI for multiple myeloma treatment
The Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, announced the US Food and Drug Administration’s approval…
Ayala Pharmaceuticals AL102 gets FDA fast track status in desmoid tumors
Ayala Pharmaceuticals has been granted fast track designation for its oral gamma-secretase inhibitor AL102 by the US Food…
Lupin launches generic Suprep Bowel Prep Kit in the US after FDA approval
Lupin launches FDA-approved generic Suprep Bowel Prep Kit in the US, entering a $202M market and expanding its gastrointestinal portfolio.
FDA approves Opdivo and Cabometyx combo for advanced kidney cancer treatment
The U.S. Food and Drug Administration (FDA) has officially approved the combination of Bristol Myers Squibb’s Opdivo (nivolumab)…
BRILINTA FDA approval: A major step in reducing stroke risks in acute ischemic stroke and high-risk TIA patients
AstraZeneca has secured U.S. Food and Drug Administration (FDA) approval for BRILINTA (ticagrelor), expanding its use to reduce…
Masimo gets FDA clearance for Centroid patient monitoring sensor
Masimo, a US medical device company, has received clearance from the US Food and Drug Administration (FDA) for…
PADCEV, KEYTRUDA combination for advanced bladder cancer gets FDA breakthrough therapy status
PADCEV, KEYTRUDA combination : Astellas Pharma and Seattle Genetics said that the combination of PADCEV (enfortumab vedotin-ejfv) and…